Drug treatment in acute porphyria

British Journal of Clinical Pharmacology

Volumn 44, Issue 5, 1997, Pages 427-434

  Gorchein, A ^a  

^a IMPERIAL COLLEGE SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Acute poprhyria; Drugs; Haem; Safe; Treatment; Unsafe

Indexed keywords

ACETAZOLAMIDE; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARDIOVASCULAR AGENT; CHLORAL HYDRATE; CODEINE; ENALAPRIL; ERGOT ALKALOID; FENTANYL; FUROSEMIDE; GRISEOFULVIN; HEME; HEME ARGINATE; IMIPRAMINE; METFORMIN; METHYLDOPA; METOCLOPRAMIDE; PENICILLIN DERIVATIVE; PENTAZOCINE; PIROXICAM; PIVAMPICILLIN; PORPHYRIN; PROGESTERONE; RIFAMPICIN; SEX HORMONE; TESTOSTERONE; THEOPHYLLINE; UNINDEXED DRUG;

DRUG CHOICE; DRUG CONTRAINDICATION; DRUG SAFETY; DRUG USE; EARLY DIAGNOSIS; GENETIC DISORDER; HEPATIC PORPHYRIA; HUMAN; PRIORITY JOURNAL; REVIEW; SYMPTOM;

EID: 0030722535     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.t01-1-00609.x     Document Type: Review

References (75)

1. Kappas A, Sassa S, Galbraith RA, Nordmann Y. The porphyrias. In The metabolic and molecular bases of inherited disease. Seventh Edition, eds Scriver CR, Beaudet AL, Sly WS, Valle D, New York: McGraw-Hill, 1995: 2103-2159.
2. McColl KEL, Dover S, Fitzsimons E, Moore MR. Porphyrin metabolism and the porphyrias. In Oxford Textbook of Medicine, Third Edition, eds Weatherall DJ, Ledingham JGG, Warrell DA, Oxford: Oxford University Press, 1996: 1388-1399.
3. Long C, Smyth SJ, Woolf J, et al. Detection of latent variegate porphyria by fluorescence emission spectroscopy of plasma. Br J Dermatol 1993; 129: 9-13.
4. Strand LJ, Meyer UA, Felsher BF, Redeker AG, Marver HS. Decreased red cell uroporphyrinogen I synthase activity in intermittent acute porphyria. J Clin Invest 1972; 51: 2530-2536.
5. Guo R, Lim CK, Peters TJ. High performance liquid Chromatographic assays for protoporphyrin oxidase and ferrochelatase in human leucocytes. J Chromatogr 1991; 566: 383-396.
6. Rossi E, Curnow DH. Porphyrins. In Hplc of small molecules a practical approach, ed Lim CK, Oxford: IRL Press 1986: 261-303.
7. Deybach JC, Puy H. Porphobilinogen deaminase gene structure and molecular defects. J Bioenerg Biomembr 1995; 27: 197-205.
8. Tschudy DP. The influence of hormonal and nutritional factors on the regulation of liver heme biosynthesis. In Handbook of Experimental Pharmacology, Heme and hemoproteins, eds de Matteis F, Aldridge WN, Berlin: Springer Verlag, 1978: 255-271.
9. Herrick AL, McColl KEL, Moore MR, Cook A, Goldberg A. Controlled trial of haem arginate in acute hepatic porphria. Lancet 1989; 1: 1295-1297.
10. Mustajoki P, Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 1993; 153: 2004-2008.
11. Galbraith RA, Kappas A. Pharmacokinetics of tin-mesoporphyrin in man and the effects of tin-chelated porphyrins on hyperexcretion of heme pathway precursors in patients with acute inducible porphyria. Hepatology 1989; 9: 882-888.
12. Dover SB, Moore MR, Fitzsimmons EJ, Graham A, McColl KEL. Tin protoporphyrin prolongs the biochemical remission produced by haem arginate in acute hepatic porphyria. Gastroenterology 1993; 105: 500-506.
13. Mark JA, Maines MD. Tin-protoporphyrin-mediated disruption in vivo of heme oxygenase-2 protein integrity and activity in rat brain. Pediatr Res 1992; 32: 324-329.
14. Cable EE, Pepe JA, Karamitsios NC, Lambrecht R Bonkowsky HL. Differential effects of metalloporphyrins on messenger RNA levels of δ-aminolevulinate synthase and heme oxygenase. Studies in cultured chick embryo liver cells. J Clin Invest 1994; 94: 649-654.
15. Yeung Laiwah AC, McColl KEL. Management of attacks of acute porphyria. Drugs 1987; 34: 604-616.
16. Moore MR, McColl KEL. Therapy of the acute porphyrias. Clin Biochem 1989; 22: 181-188.
17. Waldenstrom J. Studien uber Porphyrie. Acta Med Scand 1937; Suppl 82: 1-254.
18. Dean G. The prevalence of the porphyrias. SA J Lab Clin Med 1963; 9: 145-151.
19. Maxwell JD, Meyer UA. Pharmacogenetics in the field of drug metabolism: drug sensitivity in hereditary hepatic porphyria. In Heme and hemoproteins, eds de Matteis F, Aldridge WN, Berlin: Springer Verlag, 1978: 239-254.
20. Granick S. The induction in vitro of the synthesis of δ-aminolevulinic acid synthetase in chemical porphyria: a response to certain drugs, sex hormones, and foreign chemicals. J Biol Chem 1966; 241: 1359-75.
21. Marks GS, McCluskey SA, Mackie JE, Riddick DS, James CA. Interaction of chemicals with cytochrome P-450: implications for the porphyrinogenicity of drugs. Clin Biochem 1989; 22: 169-175.
22. De Matteis F. Drug interactions in experimental hepatic porphyria. A model for the exacerbation by drugs of human variegate porphyria. Enzyme 1973; 16: 266-275.
23. Anderson KE. Effects of antihypertensive drugs on hepatic heme biosynthesis, and evaluation of ferrochelatase inhibitors to simplify testing of drugs for heme pathway induction. Biochim Biophys Acta 1978; 543: 313-327.
24. De Matteis F. Hepatic porphyrias. In Handbook of Experimental Pharmacology, Heme and hemoproteins, eds de Matteis F, Aldridge WN, Berlin: Springer Verlag, 1978: 129-155.
25. Peters PG, Sharma ML, Hardwicke DM, Piper WN. Sulphonamide inhibition of rat hepatic uroporphyrinogen 1 synthetase activity and the biosynthesis of heme. Arch Biochem Biophys 1980; 201: 88-94.
26. Sinclair PR, Healey JF, Sinclair JF, Bonkowsky HL. Induction of 5-aminolevulinate synthase in chick embryo liver by propylisopropylacetamide does not involve destruction of cytochrome P450. Biochem J 1981; 200: 709-710.
27. Hamilton JW, Bernent WJ, Sinclair PR, Sinclair JF, Wetterhan KE. Expression of 5-aminolaevulinate synthase and cytochrome P450 mRNAs in chicken embryo hepatocytes in vivo and in culture. Effect of porphyrinogenic drugs and haem. [erratum Biochem J 1989; 257: following 934] Biochem J 1988; 255: 267-275.
28. Dogra SC, Hahn CN, May BK Superinduction by cycloheximide of cytochrome P4502H1 and 5-aminolevulinate synthase gene transcription in chick embryo liver. Arch Biochem Biophys 1993; 300: 531-534.
29. Jover R, Hoffmann K, Meyer UA. Induction of 5-aminolevulinate synthase by drugs is independent of increased apocytochrome P450 synthesis. Biochem Biophys Res Commun 1996; 226: 152-157.
30. Marks GS. The effect of chemicals on hepatic heme biosynthesis. In Handbook of Experimental Pharmacology, Heme and hemoproteins, eds de Matteis F, Aldridge WN, Berlin: Springer Verlag, 1978: 201-237.
31. Lindberg RL, Porcher C, Grandchamp B, et al. Porphobilinogen deaminase deficiency in mice causes a neuropathy resembling that of human hepatic porphyria. Nat Genet 1996; 12: 195-199.
32. Tschudy DP, Perlroth MG, Marver HS, Collins A, Hunter G Jr, Rechcigl M Jr. Acute intermittent porphyria: the first 'overproduction disease' localized to a specific enzyme. Proc Nat Acad Sci USA 1965; 53: 841-847.
33. Nakao K, Wada O, Kitamura T, Uono K, Urata G. Activity of aminolevulinic acid synthetase in normal and porphyric livers. Nature 1966; 210: 838-839.
34. Strand LJ, Felsher BF, Redeker AG, Marver HS. Heme biosynthesis in intermittent acute porphyria: decreased hepatic conversion of porphobilinogen to porphyrins and increased delta aminolevulinic acid synthetase activity. Proc Nat Acad Sci USA 1970; 67: 1315-1320.
35. Sweeney VP, Pathak MA, Asbury AK. Acute intermittent porphyria. Increased ALA synthetase activity during an acute attack. Brain 1970; 93: 369-380.
36. Anderson KE, Alvares AP, Sassa S, Kappas A. Studies in Porphyria V. Drug oxidation rates in hereditary hepatic porphyria. Clin Pharmacol Ther 1976; 19: 47-54.
37. Ostrowski J, Kostrzewska E, Michalak T, Zawirska B, Medrzejewski W, Gregor A. Abnormalities in liver function and morphology and impaired aminopyrine metabolism in hereditary hepatic porphyrias. Gastroenterology 1983; 85: 1131-1137.
38. Herrick A, McColl KL, McLellan A, Moore MR, Brodie MJ, Goldberg A. Effect of haem arginate therapy on porphyrin metabolism and mixed function oxygenase activity in acute hepatic porphyria. Lancet 1987; ii: 1178-1179.
39. Bonkovsky HL, Healey JF, Lourie AN, Gerron GG. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol 1991; 86: 1050-1056.
40. Mustajoki P, Himberg JJ, Tokola O, Tenhunen R. Rapid normalization of antipyrine oxidation by heme in variegate porphyria. Clin Pharmacol Ther 1992; 51: 320-324.
41. Disler PB, Blekkenhorst GH, Eales L, Moore MR, Straughan J. Guidelines for drug prescription in patients with the acute porphyrias. SA Med J 1982; 61: 656-660.
42. Zimmer S, Taub H, Marks GS. A comparison of the porphyrin-inducing activity of barbiturates and benzodiazepines in chick embryo liver cells. Can J Physiol Pharmacol 1980; 58: 991-995.
43. Eales L. Porphyria and the dangerous life-threatening drugs. SA MedJ 1979; 56: 914-917.
44. Blanloeil Y, Deybach JC, Portier D Joyau M, Nordmann Y. Anaesthesia for hepatic porphyrias. Ann Fr Anesth Reanim 1989; 8: 109-125.
45. Moore MR, McColl KEL. Porphyria drug lists. Glasgow: Hunter Press, 1990.
46. Hift RJ, Meissner PN, Meissner DM. Porphyria. A guide for people with porphyria and their doctors. Cape Town: Medical Research Council and University of Cape Town Liver Research Centre, 1989.
47. Wilson JHP, de Rooij FWM. Gastro-intestinal neurologic and psychiatric manifestations of acute porphyria. Rotterdam: Porphyria Research Centre, 1994.
48. Anonymous. Acute porphyrias. In British National Formulary, Number 33, ed Mehta DK, London: British Medical Association, 1997: 409-410.
49. Mustajoki P, Heinonen J. General anesthesia in 'inducible' porphyrias. Anesthesiology 1980; 53: 15-20.
50. Kauppinen R, Mustajoki P. Prognosis of acute porphyria: Occurrence of acute attacks, precipitating factors, and associated diseases. Medicine 1992; 71: 1-13.
51. Nordmann Y, de Verneuil H, Deybach J-C, Delfau M-H, Grandchamp B. Molecular genetics of porphyrias. Ann Med 1990; 22: 387-391.
52. Grandchamp B, Picat C, Mignotte V, et al. Tissue-specific splicing mutation in acute intermittent porphyria. Proc Natl Acad Sci USA 1989; 86: 661-664.
53. Gu XF, de Rooij F, Voortman G, et al. Detection of eleven mutations causing acute intermittent porphyria using denaturing gradient gel electrophoresis. Hum Genet 1994; 93: 47-52.
54. Kauppinen R, Mustajoki S, Pihlaja H, Peltonen L, Mustajoki P. Acute intermittent porphyria in Finland: 19 mutations in the porphobilinogen deaminase gene. Hum Mol Genet 1995; 4: 215-222.
55. Llewellyn DH, Scobie GA, Urquhart AJ, et al. Acute intermittent porphyria caused by defective splicing of porphobilinogen deaminase RNA: a synonymous codon mutation at - 22 bp from the 5′ splice site causes skipping of exon 3. J Med Genet 1996; 33: 437-438.
56. Kauppinen R, Timonen K, Mustajoki P. Treatment of the porphynas. Ann Med 1994; 26: 31-38.
57. Dover SB, Plenderleith L, Moore MR, McColl KEL. Safety of general anaesthesia and surgery in acute hepatic porphyria. Gut 1994; 35: 1112-1115.
58. Harrison GG, Meissner PN, Hift RJ. Anaesthesia for the porphyric patient. Anaesthesia 1993; 48: 417-421.
59. Jeans JB, Savik K, Gross CR, et al. Mortality in patients with acute intermittent porphyria requiring hospitalization: A United States case series. Am J Med Genet 1996; 65: 269-273.
60. Whatley SD, Roberts AG, Elder GH. De-novo mutation and sporadic presentation of acute intermittent porphyria. Lancet 1995; 346: 1007-1008.
61. Perlroth MGH, Marver HS, Tschudy DP. Oral contraceptive agents and the management of acute intermittent porphyria. JAMA 1965; 194: 1037-1042.
62. Gross U, Honcamp M, Daume E, Frank M, Dusterberg B, Doss MO. Hormonal oral contraceptives, urinary porphyrin excretion and porphyrias. Horm Metab Res 1995; 27: 379-383.
63. Anderson KE. LHRH analogues for hormonal manipulation in acute intermittent porphyria. Semin Hematol 1989; 26: 10-15.
64. Herrick AL, McColl KE, Wallace AM, Moore MR, Goldberg A. LHRH analogue treatment for the prevention of premenstrual attacks of acute porphyria. Q J Med 1990; 75: 355-363.
65. Savage MW, Reed P, Orrman-Rossiter SL, Weincove C, Anderson DC. Acute intermittent porphyria treated by testosterone implant. Postgrad Med J 1992; 68: 479-481.
66. Wetterberg L, Olsson MB, Alm-Agvald I. Estrogen treatment caused acute attacks of porphyria. Lakartidningen 1995; 92: 2197-2201.
67. Hift R, Sohnius U, Meissner PN. Safety of vancomycin in acute porphyria. Br J Clin Pharmacol 1990; 29: 273-275.
68. Moore MR, Disler PB. Drug-induction of the acute porphyrias. Adv Drug React Ac Pois Rev 1983; 2: 149-189.
69. Suzuki A, Aso K, Ariyoshi C, Ishimaru M. Acute intermittent porphyria and epilepsy: safety of clonazepam. Epilepsia 1992; 33; 108-111.
70. Bonkowsky HL, Sinclair PR, Emery S, Sinclair JF. Seizure management in acute hepatic porphyria: risks of valproate and clonazepam. Neurology 1980; 30: 588-593.
71. Tatum IV WO, Zachariah SB. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology 1995; 45: 1216-1217.
72. Yandel MI, Watters MR. Treatment of complex partial status epilepticus unmasking acute intermittent porphyria in a patient with resected anaplastic glioma. Clin Neurol Neurosurg 1995; 97: 261-263.
73. Vas FJ, Salcedo MS. Fluoxetine treatment of depressive symptoms in acute intermittent porphyria. J Clin Psychiatr 1991; 52: 138.
74. Dover SB, Graham A, Moore MR, McColl KEL. Lofepramine-a safe anti-depressant in acute hepatic porphyria? J Psychopharmacol 1994; 8: 104-108.
75. Gorchein A. Drug treatment of hypertension in acute intermittent porphyria: doxazosin and amlodipine. Br J Clin Pharmacol 1997; 43: 339-340.